37057711|t|The DEXA-CORT trial: study protocol of a randomised placebo-controlled trial of hydrocortisone in patients with brain tumour on the prevention of neuropsychiatric adverse effects caused by perioperative dexamethasone.
37057711|a|INTRODUCTION: The synthetic glucocorticoid dexamethasone can induce serious neuropsychiatric adverse effects. Dexamethasone activates the glucocorticoid receptor (GR) but, unlike endogenous cortisol, not the mineralocorticoid receptor (MR). Moreover, dexamethasone suppresses cortisol production, thereby eliminating its MR binding. Consequently, GR overactivation combined with MR underactivation may contribute to the neuropsychiatric adverse effects of dexamethasone. The DEXA-CORT trial aims to reactivate the MR using cortisol to reduce neuropsychiatric adverse effects of dexamethasone treatment. METHODS AND ANALYSIS: The DEXA-CORT study is a multicentre, randomised, double-blind, placebo-controlled trial in adult patients who undergo elective brain tumour resection treated perioperatively with high doses of dexamethasone to minimise cerebral oedema. 180 patients are randomised between treatment with either two times per day 10 mg hydrocortisone or placebo during dexamethasone treatment. The primary study outcome is the difference in proportion of patients scoring >=3 points on at least one of the Brief Psychiatric Rating Scale (BPRS) questions 5 days postoperatively or earlier at discharge. Secondary outcomes are neuropsychiatric symptoms, quality of sleep, health-related quality of life and neurocognitive functioning at several time points postoperatively. Furthermore, neuropsychiatric history, serious adverse events, prescribed (psychiatric) medication and referrals or evaluations of psychiatrist/psychologist and laboratory measurements are assessed. ETHICS AND DISSEMINATION: The study protocol has been approved by the Medical Research Ethics Committee of the Leiden University Medical Center, and by the Dutch competent authority, and by the Institutional Review Boards of the participating sites. It is an investigator-initiated study with financial support by The Netherlands Organisation for Health Research and Development (ZonMw) and the Dutch Brain Foundation. Results of the study will be submitted for publication in a peer-reviewed journal. TRIAL REGISTRATION NUMBER: NL6726 (Netherlands Trial Register); open for patient inclusion. EudraCT number 2017-003705-17.
37057711	9	13	CORT	Chemical	MESH:D003348
37057711	80	94	hydrocortisone	Chemical	MESH:D006854
37057711	98	106	patients	Species	9606
37057711	112	124	brain tumour	Disease	MESH:D001932
37057711	146	178	neuropsychiatric adverse effects	Disease	MESH:D064420
37057711	203	216	dexamethasone	Chemical	MESH:D003907
37057711	261	274	dexamethasone	Chemical	MESH:D003907
37057711	294	326	neuropsychiatric adverse effects	Disease	MESH:D064420
37057711	328	341	Dexamethasone	Chemical	MESH:D003907
37057711	356	379	glucocorticoid receptor	Gene	2908
37057711	381	383	GR	Gene	2908
37057711	408	416	cortisol	Chemical	MESH:D006854
37057711	426	452	mineralocorticoid receptor	Gene	4306
37057711	454	456	MR	Gene	4306
37057711	469	482	dexamethasone	Chemical	MESH:D003907
37057711	494	502	cortisol	Chemical	MESH:D006854
37057711	539	541	MR	Gene	4306
37057711	565	567	GR	Gene	2908
37057711	597	599	MR	Gene	4306
37057711	638	670	neuropsychiatric adverse effects	Disease	MESH:D064420
37057711	674	687	dexamethasone	Chemical	MESH:D003907
37057711	698	702	CORT	Chemical	MESH:D003348
37057711	732	734	MR	Gene	4306
37057711	741	749	cortisol	Chemical	MESH:D006854
37057711	760	792	neuropsychiatric adverse effects	Disease	MESH:D064420
37057711	796	809	dexamethasone	Chemical	MESH:D003907
37057711	852	856	CORT	Chemical	MESH:D003348
37057711	941	949	patients	Species	9606
37057711	971	983	brain tumour	Disease	MESH:D001932
37057711	1037	1050	dexamethasone	Chemical	MESH:D003907
37057711	1063	1078	cerebral oedema	Disease	MESH:D001929
37057711	1084	1092	patients	Species	9606
37057711	1162	1176	hydrocortisone	Chemical	MESH:D006854
37057711	1195	1208	dexamethasone	Chemical	MESH:D003907
37057711	1281	1289	patients	Species	9606
37057711	1338	1349	Psychiatric	Disease	MESH:D001523
37057711	1451	1476	neuropsychiatric symptoms	Disease	MESH:D001523
37057711	1611	1627	neuropsychiatric	Disease	MESH:C000631768
37057711	1673	1684	psychiatric	Disease	MESH:D001523
37057711	1797	1821	ETHICS AND DISSEMINATION	Disease	MESH:D009103
37057711	2372	2379	patient	Species	9606
37057711	Association	MESH:D064420	4306
37057711	Negative_Correlation	MESH:D006854	MESH:D064420
37057711	Association	MESH:D003907	4306
37057711	Positive_Correlation	MESH:D003907	2908
37057711	Negative_Correlation	MESH:D003907	MESH:D001929
37057711	Positive_Correlation	MESH:D003907	MESH:D064420
37057711	Negative_Correlation	MESH:D003907	MESH:D006854
37057711	Negative_Correlation	MESH:D006854	MESH:D001932
37057711	Negative_Correlation	MESH:D003907	MESH:D001932
37057711	Positive_Correlation	MESH:D064420	2908
37057711	Positive_Correlation	MESH:D006854	4306

